Dare Bioscience Inc reports results for the quarter ended in March - Earnings Summary

Dare Bioscience

14/05/2024 15:23

* Dare Bioscience Inc  DARE.OQ  reported a quarterly
adjusted loss
of 7 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -9 cents.  The mean expectation of three analysts for the
quarter was for a loss of 6 cents per share. 
    * Revenue was $9.30 million​; analysts expected $260.50
thousand. 
    * Dare Bioscience Inc's reported EPS for the quarter was a
loss
of 7 cents​.
    * The company reported a quarterly loss of $6.76 million.
    * Dare Bioscience Inc shares had fallen by 35.7% this
quarter and
gained 2.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Dare Bioscience
Inc is $6.00 
This summary was machine generated from LSEG data May 14 at
02:22 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.06          -0.07          Missed
 Dec. 31 2023      -0.10          -0.06          Beat
 Sep. 30 2023      -0.10          -0.09          Beat
 Jun. 30 2023      -0.10          -0.10          Met